European Union Approves Amgevita for Crohn’s Disease and Ulcerative Colitis

European Union Approves Amgevita for Crohn’s Disease and Ulcerative Colitis
The European Union has approved Amgen‘s Amgevita, a biosimilar to Humira (adalimumab), as a treatment for inflammatory bowel diseases (IBDs) such as Crohn’s and ulcerative colitis. The European Commission decision applies to moderate-to-severe Crohn’s disease and moderate-to-severe ulcerative colitis in adults, and moderate-to-severe Crohn’s in children at least 6 years old. Amgevita can also be used to

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *